Tim Peterson | Scientific Director, Dermal Drug Delivery
Kindeva Drug Delivery

Day 2 - Wednesday 1st April @ 15:25

Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery

li>
•     Scaling Innovation: Expanding novel delivery formats in LMICs needs strong public-private partnerships and tech transfer. 
•     System Readiness: Promising technologies face adoption barriers due to limited infrastructure and regulation (PPP and tech-transfer). Are health systems and delivery programs equipped for novel formats?
•     Formulation Focus: Adjuvants and formulation science are key to effective, scalable needle-free platforms.
•     Strategic Coordination: Aligning science, strategy, and scale-up is vital to move innovations into practice. 

Session led by: Kindeva Drug Delivery

Nikolai Petrovsky, Chairman, Vaxine Pty.

×

Nikolai Petrovsky / Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery

Nikolai Petrovsky, Chairman,
Vaxine Pty.

Nikolai is Professor of Immunology and Infectious Disease at the Australian Respiratory and Sleep Medicine Institute in Adelaide and is a leading physician-scientist in the area of vaccine and adjuvant development. He is Research Director for Vaxine, an Australian biotechnology company. His...

CloseMore

Lee-Jah Chang, Head of Clinical Development, Vaccines and Immune Therapies, AstraZeneca

×

Lee-Jah Chang / Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery

Lee-Jah Chang, Head of Clinical Development, Vaccines and Immune Therapies,
AstraZeneca

Lee-Jah joined AstraZeneca in 2021 and currently is the Vice President, Head of Clinical Development for Vaccines and Immune Therapies where he leads the Early and Late V&I clinical teams. His team is responsible for the clinical studies that support a clinical development plan and the clinical ...

CloseMore

Moderator: Matthew Hepburn, Partner, Avinora Health

×

Matthew Hepburn / Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery

Matthew Hepburn, Partner,
Avinora Health

Dr. Hepburn is currently co-lead of Avinora Health, an independent consulting service covering the landscape of breakthrough health technology in the interface with infectious diseases. He recently served as the Executive Vice President of R&D at Panther Life Science, which focused on...

CloseMore

Tim Peterson, Scientific Director, Dermal Drug Delivery, Kindeva Drug Delivery

×

Tim Peterson / Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery

Tim Peterson, Scientific Director, Dermal Drug Delivery,
Kindeva Drug Delivery

Tim Peterson is the Scientific Director, Dermal Drug Delivery at Kindeva Drug Delivery’s Woodbury, MN headquarters. Tim has been developing and scaling-up transdermal and microneedle-enabled drug delivery systems for over 35 years.Prior to Kindeva, Tim led a group focused on the development of new...

CloseMore

David Saunders, Medical Director, Lumen Bioscience

×

David Saunders / Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery

David Saunders, Medical Director,
Lumen Bioscience

Dr. Saunders has served as Medical Director, Lumen Bioscience, Seattle, WA since Sept 2025.  Lumen is a clinical-stage biotechnology company with a mission to provide low-cost biologics to prevent and treat a broad portfolio of diseases.  Lumen’s platform Lumen's patented technology employs...

CloseMore